MOTS (MOTS) Stock Price & Analysis
MOTS (MOTS) rose 0.00% to USD 0 as of June 10, 2026 at 04:38 UTC, according to Nexqual real-time market data.
MOTS last closed at USD 0; the session ranged USD 0–0 on volume of 1 shares. Market capitalization is $638, with a 52-week range of USD 0–0.1 (PNK). Source: Nexqual, June 10, 2026 at 04:38 UTC.
Key Statistics (as of June 10, 2026 at 04:38 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.1 |
| Volume | 1 shares |
| Market Cap | $638 |
| Exchange | PNK |
Technical Analysis (MOTS)
Nexqual's technical model rates MOTS "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 04:38 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (MOTS)
Wall Street analysts rate MOTS "None", per Nexqual as of June 10, 2026 at 04:38 UTC.
| Consensus Rating | None |
|---|
Earnings (MOTS)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-12-31 | USD -4.03 vs est -4.19 ▲ beat |
| 2023-09-30 | USD -4.28 vs est -6.2 ▲ beat |
| 2023-06-30 | USD -6 vs est -9.1 ▲ beat |
| 2023-03-31 | USD -13.8 vs est -14.85 ▲ beat |
Source: Nexqual, June 10, 2026 at 04:38 UTC.
Financials & Fundamentals (MOTS)
| Total Revenue | $327,000 |
|---|---|
| Revenue Growth (YoY) | +14.30% |
| Gross Margin | -24.46% |
| Operating Margin | -3165.63% |
| Profit Margin | +0.00% |
| ROE | -1069.02% |
| Debt / Equity | 79.49 |
| Current Ratio | 1.74 |
| Total Cash | $4.94M |
| Total Debt | $2.44M |
| Free Cash Flow | $-4.40M |
Source: Nexqual, June 10, 2026 at 04:38 UTC.
Financial Health Score (MOTS)
Nexqual rates MOTS's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 04:38 UTC.
| Growth | Critical — Revenue -46% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $5M cash vs $2M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$4M, burning cash |
| Efficiency | Critical — ROE -1069%, ROA -62.0% |
Ownership (MOTS)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +5.25% |
| Shares Outstanding | 6.39M |
| Float | 5.77M |
| Short % of Float | +0.45% |
Source: Nexqual, June 10, 2026 at 04:38 UTC.
Leadership (MOTS)
MOTS is led by Ravit Ram (age 50), CFO & VP of Global Operations, per Nexqual as of June 10, 2026 at 04:38 UTC.
| CFO & VP of Global Operations | Ravit Ram (age 50) |
|---|---|
| President & Director | Jeff Varsalone |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NDRA | ENDRA Life Sciences Inc. | USD 4.42 | ▲ 4.49% |
| DCOY | Decoy Therapeutics Inc. | USD 5.51 | ▼ 16.64% |
| SXTC | China SXT Pharmaceuticals, Inc. | USD 1.56 | ▲ 8.33% |
| MBAI | Check-Cap Ltd. | USD 1.4 | ▲ 1.45% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:38 UTC. This page is informational and not investment advice.